Home / drug / D-0406-2026 Class II Reported 2026-04-01
Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, Single-dose 8 mL vial, Rx only, Manufactured in Greece BY: Pharmathen International S.A, Rodopi, 693 00 Greece, Manufactured For: TEVA Pharmaceuticals, Parsippany, NJ 07054, NDC 0480-9262-08. Recalled by Teva Pharmaceuticals USA, Inc
Reason for Recall Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
Advertisement
Was this product in your home? Find safe, vetted alternatives. We may earn a commission on qualifying purchases.
Browse Safer Alternatives
Recall Number D-0406-2026
Classification Class II
Status Ongoing
Category drug
Initiated 2026-03-17
Reported 2026-04-01
Distribution Nationwide in the USA
Code Info Lot:4400401, Exp.: 6/30/2026; 4401393, 4401494, 4401604, Exp.: 9/31/2026; 4500564, 4500601, 4500707, 4500796, 4500859, 4500918, 4500919, 4501006, Exp.: 3/31/2027. Source: openFDA enforcement report. WhichRecall is not affiliated with the FDA. See our disclaimer .